Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy
- 1 June 1986
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 57 (15) , 1328-1334
- https://doi.org/10.1016/0002-9149(86)90213-4
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- MDL 17,043: Short- and long-term cardiopulmonary and clinical effects in patients with heart failureJournal of the American College of Cardiology, 1985
- MDL 17,043 therapy in severe congestive heart failure: Characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical responseJournal of the American College of Cardiology, 1985
- Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failureAmerican Heart Journal, 1985
- Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patientsJournal of the American College of Cardiology, 1984
- Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failureJournal of the American College of Cardiology, 1984
- Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performanceThe American Journal of Cardiology, 1984
- The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure.Circulation, 1983
- Cardiovascular Properties of a New Cardiotonic AgentJournal of Cardiovascular Pharmacology, 1982
- Comparative responses to dobutamine and nitroprusside in patients with chronic low output cardiac failure.Circulation, 1977
- Hemodynamic effect of dobutamine in patients with severe heart failureThe American Journal of Cardiology, 1975